Physician profile
Michael Solliday
NPI 1285739235
$3,730.91
in general payments reported to CMS, 2019-2025
37 companies · $519 in 2025
The $519 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $137 · 2021: $443 · 2022: $568 · 2023: $487 · 2024: $488 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $432.22 | 2021-2024 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $377.62 | 2019-2025 | |
| Neotract INC. | $328.99 | 2019 | |
| Urogen Pharma, INC. | $259.22 | 2021-2025 | |
| Astellas Pharma US INC | $187.99 | 2019-2023 | Myrbetriq |
| Antares Pharma, INC. | $182.86 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $170.06 | 2019-2025 | Erleada |
| Merck Sharp & Dohme LLC | $166.00 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Ferring Pharmaceuticals INC. | $129.02 | 2019-2025 | Adstiladrin |
| Tolmar, INC. | $124.55 | 2023-2025 | Eligard, Jatenzo |
| Abbvie INC. | $121.17 | 2019-2024 | |
| Pfizer INC. | $95.68 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $92.91 | 2023-2025 | Orgovyx, Gemtesa |
| Myovant Sciences INC. | $88.94 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $87.28 | 2019-2023 | Xiaflex |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Solliday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.